The Unseen Cost of Weight Loss? Dentists Warn of 'Ozempic Teeth'

The 'Skinny Pen' Phenomenon: A Look at India's Weight Loss Drug Revolution

Navigating the Untamed Frontier: Why the GLP-1 Market Still Feels Like the Wild West

Wegovy in Vials? Novo Nordisk's Strategic Shift to Boost Supply and Challenge Eli Lilly

The Weight-Loss Drug Wars: Novo Nordisk Eyes Vials for Wegovy in High-Stakes Battle

GLP-1 Medications: Separating Hype from Health with Expert Insights

Navigating the New Frontier of Weight Loss: Scrutiny Mounts on Telehealth Providers

Novo Nordisk Doubles Down: Lawsuit Against Hims & Hers Continues Despite 'Wegovy Pill' Plans Scrapped

Weight-Loss Drug Wars Escalate: Novo Nordisk Sues Hims & Hers Over Compounded Semaglutide

The Weight-Loss Revolution: Telehealth Giant Hims & Hers Dives into the GLP-1 Market

Hims & Hers Hits the Brakes: Generic Wegovy Plans Abandoned Amidst GLP-1 Market Shifts

The Shifting Sands of US Drug Pricing: Why Big Pharma Investors are on Edge

Eli Lilly CEO Sees Medicare Support as Game-Changer for New Oral Obesity Pill

Unpacking GLP-1 Drugs: A Human's Guide to the Latest Metabolic Marvels

The Ozempic Phenomenon: Navigating the Hype Around New Weight Loss Drugs

The Pharmaceutical Frontier: Navigating Breakthroughs, Billions, and Bitter Debates

The Whole Truth About GLP-1 Drugs: Why Lasting Weight Loss Needs More Than Just a Prescription

The Rebound Effect: What Happens When You Stop Taking Popular Weight-Loss Medications?

The Weight of Hope: Unpacking America's Obesity Pill Revolution

The Delhi High Court's Landmark Ruling on Semaglutide: A Win for Accessibility

The Unforeseen Impact of GLP-1 Drugs: Beyond Weight Loss, a New Hope Emerges

The Pharmaceutical Pulse: A Year-End Reflection on Innovation, Politics, and Public Trust in 2025

The Great Unbundling: Why Weight Loss Drug Prices Are Finally Coming Down

The Frustrating Wait: Why Wegovy Remains a Distant Dream for Many Canadians

A Global Shift: WHO Declares Obesity a Chronic Disease, Backs GLP-1 Drugs with Holistic Care

A Closer Look: Australia Sounds the Alarm on Popular GLP-1 Weight Loss Medications

Major Win: Delhi High Court Greenlights Dr. Reddy's for Export-Only Weight-Loss Drug Production

A Global Health Crossroads: WHO's Conditional Embrace of Ozempic-Class Drugs for Obesity

GLP-1 Medications: A Game-Changer, But Not a Solo Act – The WHO Weighs In

The Whole Picture: Why GLP-1 Weight Loss Drugs Aren't a Solo Act, According to WHO

Eli Lilly's Zepbound Gets a Significant Price Drop: What It Means for Patients and the Market

The Great Pharma Race: GLP-1s, Billions, and the Battle for What's Next

The WHO's New Stance on GLP-1s: Guiding the Revolution Responsibly

The Dawn of a New Era in Weight Loss Medicine

A New Era for Weight Loss: The Revolution of GLP-1 Pills and Monthly Shots

The Curious Case of Microdosing Obesity Drugs: A New Trend or a Risky Gamble?

Novo Nordisk's Alzheimer's Trial: A Minor Blip for a Pharma Giant

Navigating Pregnancy and GLP-1 Medications: What a Recent Study Suggests

Novo Nordisk's Alzheimer's Trial Setback: A Closer Look